Physician profile
Pushpa Latta
NPI 1770162794
$909.75
in general payments reported to CMS, 2019-2025
15 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $89.64 · 2023: $203 · 2024: $460 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $820.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $185.45 | 2023-2025 | Repatha, Otezla, Otezla |
| Exact Sciences Corporation | $145.40 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.12 | 2022-2025 | Xifaxan |
| Dexcom, INC. | $83.21 | 2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $69.47 | 2024 | |
| Novo Nordisk INC | $67.74 | 2024-2025 | Rybelsus, Ozempic |
| Alk-Abello, INC | $56.15 | 2024-2025 | Grastek, Odactra, Ragwitek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.37 | 2023 | Jardiance |
| Sanofi Pasteur INC. | $31.70 | 2023-2025 | |
| Astellas Pharma US INC | $21.86 | 2024 | Veozah |
| Daiichi Sankyo INC. | $20.75 | 2025 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $18.37 | 2023 | Farxiga |
| Medtronic, INC. | $16.91 | 2023 | Minimed 780g |
| Indivior INC. | $16.06 | 2024 | Sublocade |
| Merck Sharp & Dohme LLC | $14.19 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pushpa Latta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.